Effect of mesalasine in treatment of distal inflammation of intestine.

Phase 2

• Conditions: lcerative Colitis.; Crohn disease of large intestine

• Registration Number: IRCT201604307080N3
• Lead Sponsor: Vice Chancellor for research of Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Pateints older than 15 years old that have ulcerative colitis upon endoscopic and histologic criteria; severity of disease should be at least 3 of 12.

Exclusion criteria: Hypersensitivity to salicilate ; Active PUD; Important liver,renal or heart disease; Patients not respond to 5-ASA and on maintenance therapy with 5-ASA.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical response to each therapy groups. Timepoint: 4 weaks after startin study then every 3 month until 1 year. Method of measurement: Disease Activity Index, Simple Clinical Colitis Activity Index Questianaire.;Endoscopic response to each therapy groups. Timepoint: 4 weaks after startin study then every 3 month until 1 year. Method of measurement: Disease Activity Index, Simple Clinical Colitis Activity Inde Questianaire.;Histopathologic response to each therapy groups. Timepoint: 4 weaks after startin study then every 3 month until 1 year. Method of measurement: Disease Activity Index, Simple Clinical Colitis Activity Index Questianaire.

Secondary Outcome Measures

Name	Time	Method
Drug adverse reaction. Timepoint: 4 weaks after starting of study then every 3 month until one yesr. Method of measurement: Questionnaire.;Compliance to each treatment strategy. Timepoint: 4 weaks after starting of study then every 3 month until one yesr. Method of measurement: Questionare.